SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
ajt12181-sup-0001-TableS1.doc266K

Supplementary Methods

IVUS procedure

Table S1: Demographic and transplant characteristics of the patients within the IVUS subpopulation and compared to the non-IVUS population

Table S2: Most frequent nonfatal serious adverse events (≥2% of any treatment group; safety population)

Table S3: Adverse events leading to study drug discontinuation (≥1% of any treatment group; safety population)

Table S4: Baseline clinical characteristics in the everolimus 3.0 mg cohort (ITT population)

Table S5: Efficacy outcomes in the everolimus 3.0 mg cohort (n = 168) (ITT population)

Table S6: Relevant safety parameters in the everolimus 3.0 mg cohort (n = 167) (safety population)

Table S7: Laboratory values in the everolimus 3.0 mg cohort (n = 167) (safety population, on-treatment patients; last observation carried forward [LOCF] method)

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.